Home > Insider Trading > Filing (0001209191-20-062919)

Filing Details

Accession Number:: 0001209191-20-062919
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-12-11 16:05:09
Reporting Period:: 2020-12-10

Accepted Time:: 2020-12-11 16:05:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1674416	Crispr Therapeutics Ag	CRSP	Biological Products, (No Disgnostic Substances) (2836)	473173478

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1682019	Samarth Kulkarni	C/O Crispr Therapeutics, Inc. 610 Main Street Cambridge MA 02139	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares	Acquisiton	2020-12-10	20,000	$1.81	189,189	No	4	M	Direct
Common Shares	Disposition	2020-12-10	5,500	$141.17	183,689	No	4	S	Direct
Common Shares	Disposition	2020-12-10	5,034	$141.98	178,655	No	4	S	Direct
Common Shares	Disposition	2020-12-10	6,766	$142.75	171,889	No	4	S	Direct
Common Shares	Disposition	2020-12-10	2,100	$143.71	169,789	No	4	S	Direct
Common Shares	Disposition	2020-12-10	600	$144.97	169,189	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Stock Option (Right to Buy)	Disposition	2020-12-10	20,000	$0.00	20,000	$1.81

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
142,783		2025-09-10	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.53 to $141.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.54 to $142.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.61.00 to $143.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.63 to $144.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
he price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.95 to $145.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter.